Evaluation of the pharmacologic basis for the therapy of circulatory shock.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000804:Angiotensin II / Q000494:pharmacology / Q000627:therapeutic use; D001808:Blood Vessels / Q000187:drug effects; D004071:Digitalis Glycosides / Q000494:pharmacology / Q000627:therapeutic use; D004298:Dopamine / Q000494:pharmacology / Q000627:therapeutic use; D004837:Epinephrine / Q000494:pharmacology / Q000627:therapeutic use; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006801:Humans; D008616:Mephentermine / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000494:pharmacology / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects*; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D013565:Sympatholytics / Q000494:pharmacology* / Q000627:therapeutic use; D013566:Sympathomimetics / Q000494:pharmacology* / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D004071:Digitalis Glycosides; D005938:Glucocorticoids; D013565:Sympatholytics; D013566:Sympathomimetics; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000804:Angiotensin II; D008616:Mephentermine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine